Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone
KEYNOTE-062 (P vs C ; CPS>10), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumabplacebo plus chemotherapy (cisplatin plus fluorouracil or capecitabine)first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)92 / 90some concern
suggested
  • suggested 31 % decrease in deaths (OS) (PE)
versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-062 (P vs C ; CPS>1), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumabplacebo plus chemotherapy (5FU or capecitabine plus cisplatin)first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma256 / 250some concern
inconclusive
  • statistically significant 66 % increase in progression or deaths (PFS)
  • statistically significant 71 % decrease in objective responses (ORR)

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (all population), 2018
  NCT02370498
RCTmGC or mGEJC - L2 - all populationpembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine296 / 296some concern
inconclusive
  • statistically significant 49 % increase in progression or deaths (PFS)

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (PDL1 CPS>1), 2018
  NCT02370498
RCTmGC or mGEJC - L2 - PDL1 positivepembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)196 / 199some concern
inconclusive
  • inconclusive 18 % decrease in deaths (OS) (PE)
  • statistically significant 27 % increase in progression or deaths (PFS) (PE)